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Abstract
Background: Treatment failure at the primary site after chemoradiotherapy is a major problem in achieving a complete
response. Photodynamic therapy (PDT) with porfimer sodium (PhotofrinH) has some problems such as the requirement for
shielding from light for several weeks and a high incidence of skin phototoxicity. PDT with talaporfin sodium (Laserphyrin) is
less toxic and is expected to have a better effect compared with Photofrin PDT. However, Laserphyrin PDT is not approved
for use in the esophagus. In this preclinical study, we investigated tissue damage of the canine normal esophagus caused by
photoactivation with Laserphyrin.
Methodology/Principal Findings: Diode laser irradiation was performed at 60 min after administration. An area 5 cm oral
to the esophagogastric junction was irradiated at 25 J/cm
2, 50 J/cm
2, and 100 J/cm
2 using a three-step escalation. The
irradiated areas were evaluated endoscopically on postirradiation days 1 and 7, and were subjected to histological
examination after autopsy. The areas injured by photoactivation were 52 mm
2, 498 mm
2, and 831 mm
2 after irradiation at
25 J/cm
2, 50 J/cm
2, and 100 J/cm
2, respectively. Tissue injury was observed in the muscle layer or even deeper at any
irradiation level and became more severe as the irradiation dose increased. At 100 J/cm
2 both inflammatory changes and
necrosis were seen histologically in extra-adventitial tissue.
Conclusions/Significance: To minimize injury of the normal esophagus by photoactivation with Laserphyrin, diode laser
irradiation at 25 J/cm
2 appears to be safe. For human application, it would be desirable to investigate the optimal laser dose
starting from this level.
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Introduction
Photodynamic therapy (PDT) is a local endoscopic treatment
using a photochemical reaction induced by an oncotropic
photosensitizer and a laser [1–3]. PDT is useful for treating
superficial esophageal cancer, preventing the development of
adenocarcinoma from high-grade dysplasia in the Barrett’s
esophagus, and alleviating stenosis caused by advanced esophageal
cancer [4–6].
We have reported on the benefits of PDT as a salvage treatment
for local residues and recurrence after definitive chemoradiother-
apy (CRT) for esophageal cancer. Salvage PDT has excellent
treatment outcomes for local residues and recurrence after CRT
with a 59.5–62.0% complete response rate and a 5-year overall
survival of 36.1% without severe adverse events [7,8]. By contrast,
salvage surgery after definitive CRT is associated with high
postoperative mortality (.10%) [9,10]. Accordingly, in carefully
selected patients without metastasis, salvage PDT after definitive
CRT is a potential curative treatment option that may improve
quality of life and prolong survival.
PDT with porfimer sodium (PhotofrinH), a hematoporphyrin
derivative and the first clinically approved photosensitizer, has
clinical disadvantages such as the requirement for shielding from
light for 4–6 weeks and a high incidence (25%) of skin toxicity
because of photosensitivity [11,12]. PDT with mono-L-aspartyl
chlorin e6 (NPe6, talaporfin sodium, LaserphyrinH), a second-
generation photosensitizer, has advantages such as: 1) a shorter
period of light shielding of about 2 weeks, 2) 10% incidence of skin
toxicity because of reduced photosensitivity, and 3) expected
treatment effect in the deep-lying tissue areas with a laser at
664 nm instead of at 630 nm as used with Photofrin PDT [13,14].
The first two advantages are meaningful for patients because of
the shorter period of shielding and lower incidence of toxicity, but
the third is associated with opposite effects, i.e., an antitumor effect
and an increased risk of an adverse event such as perforation,
especially in the esophagus.
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lying tissue seems to be an advantage for eliminating residual
tumors. However, Laserphyrin PDT is approved only in Japan
and only for superficial lung cancer. No investigation has reported
on the safety of Laserphyrin PDT in esophageal cancer and the
normal esophagus. Investigating the antitumor effects of photo-
activation is also difficult because of the difficulty in developing
esophageal cancer in large animal models. However, before we
can apply Laserphyrin PDT to human esophageal disease, we
must know whether it is safe as a treatment in the esophageal wall.
To investigate the relationship between the irradiation dose and
tissue injury in the normal esophagus, we conducted a preclinical
study of Laserphyrin PDT using a canine model.
Results
General Conditions
In the 25 J/cm
2 irradiation group, one dog vomited 50 ml fluid,
and all dogs in the 50 J/cm
2 and 100 J/cm
2 irradiation groups
vomited; average volumes were 33 ml and 113 ml, respectively.
There was a tendency for vomiting to become more severe as the
irradiation dose increased.
Appetite loss was not observed in any dog in the 25 J/cm
2
irradiation group but was apparent in all dogs in the 50 J/cm
2 and
100 J/cm
2 irradiation groups. A loss of body weight was observed
on day 7 and was related to the irradiation dose: 8.3% in the 25 J/
cm
2 group, 11.2% in the 50 J/cm
2 group, and 14.8% in the
100 J/cm
2 group.
Laboratory Data (Figure 1 and Table 1)
In the 25 J/cm
2 group, the white blood cell (WBC) counts were
13.1,12.3,and12.7610
3/mm
3beforeirradiationandondays1and7
afterirradiation,respectively;thesevaluesdidnotdiffersignificantly.
Inthe50 J/cm
2group,theWBCcountincreasedfrom10.7to17.9on
day1butreturnedto12.4610
3/mm
3onday7;thevalueonday7did
not differ from that before irradiation. In the 100 J/cm
2 group, the
WBC count increased from 12.4 to 25.9610
3/mm
3 on day 1 and
remained at 23.1610
3/mm
3 onday 7.
In the 25 J/cm
2 group, C-reactive protein (CRP) concentration
increased from 1.2 to 12.3 mg/dl on day 1 and decreased to
5.5 mg/dl on day 7. In the 50 J/cm
2 group, it increased from 3.2
to 48.6 on day 1 and decreased to 22.7 on day 7. In the 100 J/cm
2
group, C-reactive protein concentration increased from 2.2 to
61.8 mg/dl on day 1 and remained high at 56.9 mg/dl on day 7.
In the 25 J/cm
2 group, serum lactate dehydrogenase (LDH)
level increased from 38.3 to 56.0 IU/L on day 1 and decreased to
45 IU/L on day 7. In the 50 J/cm
2 group, serum LDH level
increased from 49.7 to 84 IU/L on day 1 and decreased to
64.7 IU/L on day 7. In the 100 J/cm
2 group, serum LDH level
increased from 40.3 to 103 IU/L on day 1 and remained high at
117.7 IU/L on day 7.
Compared with the baseline values, the WBC count and CRP
and LDH concentrations increased with irradiation dose. The
WBC and CRP and LDH concentrations returned to the baseline
levels in the 25 J/cm
2 group but remained high or increased
further in the 100 J group.
The Laserphyrin concentration before irradiation was 20–
30 mg/ml in all dogs, except for a value of 62.3 mg/ml in one dog
in the 50 J/cm
2 group.
Endoscopic Findings (Figures 2 and 3)
In the 25 J/cm
2 group, a reddish color change was observed at
the site of irradiation of the mucosa on day 1 in two dogs, and no
change was detected in one dog. On day 7, ulceration was
observed at the site of irradiation in the sites that showed redness
on day 1, but only redness and erosion were recognized in the
other dog.
In the 50 J/cm
2 group, redness and erosion were observed at
the site of irradiation on day 1. Ulceration was observed on day 7
in all dogs, and purple color changes were observed at the ulcer
base in two dogs.
In the 100 J/cm
2 group, redness and erosion were observed at
the site of irradiation in all dogs on day 1, and a blackish-purple
color change was observed in one dog. On day 7, ulceration,
redness, and erosion appeared in all dogs, and blackish-purple
color changes occurred at the ulcer base in two dogs.
Macroscopic Findings of the Autopsy (Figure 4 and
Table 1)
In the 25 J/cm
2 group, mucosal redness and erosion were
observed in all dogs, and shallow ulceration was observed in two.
No damage was observed at the outside of the esophageal wall in
any case.
Figure 1. Laboratory data before and after irradiation. Compared with the baseline values, WBC count and CRP and LDH concentrations were
increased with increasing radiation dose. WBC count and CRP and LDH concentrations returned to the baseline values on day 7 in the 25 J/cm
2 group
but remained high, especially in the 100 J/cm
2 group.
doi:10.1371/journal.pone.0038308.g001
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2 group, ulceration with peripheral redness and
erosion were observed in all dogs, and necrosis occurred in one.
Adhesion of the esophageal adventitia to the aorta was recognized
in all dogs.
In the 100 J/cm
2 group, ulceration with peripheral redness and
erosion were observed in all dogs, and necrosis appeared in two.
Adhesion of the esophageal adventitia to the lungs was observed in
all dogs, and adhesion to the aorta was detected in two dogs. The
areas of tissue injury were 52648 mm
2, 4986431 mm
2, and
8316692 mm
2 after irradiation at 25 J/cm
2, 50 J/cm
2, and
100 J/cm
2, respectively.
Pathological Findings (Table 2)
In the 25 J/cm
2 group, only erosion was observed at the site of
irradiation in one dog, and ulceration was recognized in the other
two dogs. Cellular infiltration was observed in the mucosa,
submucosa, muscle layer, and adventitia in the 25 J/cm
2 group
and within and outside of the adventitia in the 50 J/cm
2 and
100 J/cm
2 groups. Fibrosis and hemorrhage were observed in the
submucosa, muscle layer, and adventitia in the 25 J/cm
2 group
and within and outside of the adventitia in the 50 J/cm
2 and
100 J/cm
2 groups. Necrosis was observed in the submucosa and
muscle layer in the 25 J/cm
2 group and within and outside of the
Table 1. The injured areas and serum concentration of Laserphyrin.
Irradiation energy (J/cm
2) Animal No. Injured area Laserphyrin conc.
(mean6SD, mm2) (mean6SD, mm2)
25 1 52.3647.9 24.060.67
2
3
50 4 498.36430.7 24.6622.18
5
6
100 7 831.06691.7 23.069.37
8
9
The areas of tissue injury were 52.3647.9 mm
2, 498.36430.7 mm
2, and 831.06691.7 mm
2 after irradiation at 25 J/cm
2, 50 J/cm
2, and 100 J/cm
2, respectively. These
areas tended to be more extensive as the laser dose increased. The Laserphyrin concentration before irradiation ranged from 20 to 30 mg/ml in all groups.
doi:10.1371/journal.pone.0038308.t001
Figure 2. Endoscopic findings in the esophagus on postirradiation day 1. In all dogs except one in the 25 J/cm
2 group, the mucosa at the
site of irradiation (the area at 9 o’clock) showed reddish color changes on day 1 (A–C). Redness and ischemic color changes were observed at the site
of irradiation in all dogs in the 50 J/cm
2 and 100 J/cm
2 groups (D–I).
doi:10.1371/journal.pone.0038308.g002
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irradiation in all dogs on day 7. Ulceration was observed in the 25 J/cm
2 group (A–C) but was more extensive in both the 50 J/cm
2 and 100 J/cm
2
groups (D–I).
doi:10.1371/journal.pone.0038308.g003
Figure 4. Macroscopic findings in the esophagus. Mucosal redness and ulceration were observed in all dogs in the 25 J/cm
2 group (A–C). The
areas of redness, erosion, and ulceration were more extensive in the 50 J/cm
2 and 100 J/cm
2 groups (D–I).
doi:10.1371/journal.pone.0038308.g004
PDT of Taraporfin Sodium (Laserphyrin)
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2 and 100 J/cm
2 groups. These changes
tended to be more severe as the irradiation dose increased.
No infiltration of inflammatory cells, fibrosis, hemorrhage, or
necrosis was observed in the extra-adventitial tissue in the 25 J/
cm
2 group. These changes were seen in the 50 J/cm
2 and 100 J/
cm
2 groups, and they tended to be more severe as the laser dose
increased. In one dog in the 50 J/cm
2 group, hemorrhage from
the aorta, which had adhered to the esophagus, was accompanied
by necrosis. Inflammatory changes and necrosis of the extra-
adventitial tissue were observed histologically in the 100 J/cm
2
group.
Discussion
The effects of Photofrin PDT, a first-generation PDT, depend
on the selective retention of the photosensitizer in the neoplastic
tissue. Laserphyrin PDT, a second-generation PDT, induces
a phototoxic effect when the timing of photoactivation is
associated with the peak plasma level of the photosensitizer.
Therefore, in normal tissue irradiated by Laserphyrin photo-
activation, phototoxicity would be expected even in normal tissue.
The relationship between tissue damage and the dose of laser
irradiation by Laserphyrin photoactivation remains unknown in
the esophagus. To apply Laserphyrin PDT as a treatment option
for esophageal cancer, the relationship between the laser
irradiation dose and the damage to normal tissue and neoplastic
tissue must be known.
In the present study, we evaluated, for the first time, the safety
of Laserphyrin photoactivation in the normal esophageal wall.
This in vivo study using a canine model showed that increasing the
dose of Laserphyrin irradiation from 25 J/cm
2 to 100 J/cm
2
caused more severe inflammatory changes, as shown by the
laboratory data, macroscopic damage, and histological necrosis.
Macroscopically, the ulceration and ischemic changes around the
ulcer became more severe as the dose of laser irradiation
increased. Pathologically, these changes were confined to the
mucosa after irradiation at 25 J/cm
2, whereas they appeared as
necrosis in the muscle layer after irradiation at 50 J/cm
2, and the
necrosis extended to the extra-adventitial tissue after irradiation at
100 J/cm
2.
Adverse effects, such as appetite loss, nausea, increased
inflammatory reaction, and an increase in LDH level, were
confirmed, and these were related to the degree of tissue injury in
the esophagus. Clinical symptoms were aggravated as the dose of
laser irradiation increased. Considering these effects together, we
conclude that an irradiation energy of 25 J/cm
2 was within the
safe range of Laserphyrin photoactivation in the canine normal
esophagus. Tissue fragility differs between humans and dogs, and
Table 2. Pathological findings in the injury areas.
Laser irradiation 25 J/cm2 50 J/cm2 100 J/cm2
Animal number 123456789
Cellular infiltration Mucosa ++++2++ ––+
Submucosa 2+ 2+ 2+ 2+ 2+ 3+ –3 + 2+
Muscle layer +++2+ 2+ 3+ 2+ 2+ 2+
Adventitia 2++ + 2+ 2+ 3+ 3+ 3+ 2+
Out of Adventitia –––2 ++ 2+ 2+ 2+ 2+
Fibrosis Mucosa NE NE NE NE NE NE NE NE NE
Submucosa +++2+ 2++ ––+
Muscle layer 2+ 2+ 2+ 3+ 2+ 2+ 2+ 2+ 2+
Adventitia + ––2 + 2+ 2+ 2+ 3+ 2+
Out of Adventitia – – – ++2+ 2+ 2+ 2+
Hemorrhage Mucosa NE NE NE NE NE NE NE NE NE
Submucosa 2+ 6 + 2+ 2+ 2+ ––2 +
Muscle layer + 6 + 2+ 2+ 2+ 2++ 2+
Adventitia + 662+ 2+ 2+ 2+ 2+ 3+
Out of Adventitia –––2 ++ 2+ 2+ 2+ 3+
Aorta –––––+ –––
Necrosis Mucosa –––3 + –––––
Submucosa 2++ + 3+ 2+ 3+ 3+ 3+ 2+
Muscle layer 2+ – + 3+ 2+ 3+ 3+ 3+ 3+
Adventitia NE NE NE NE NE NE NE NE NE
Out of Adventitia ––––+++2+ 2+
Aorta –––––+ –––
Notes) -: No abnormal changes, 6: Very slight, + : Slight, 2+: Moderate, 3+: Marked, NE: Not examined.
Cellular infiltration was observed in the mucosa, submucosa, muscle layer, and adventitia in the 25 J/cm
2 group. Cellular infiltration was observed within and outside of
the adventitia in the 50 J/cm
2 and 100 J/cm
2 groups. Fibrosis and hemorrhage were observed in the submucosa, muscle layer, and adventitia in the 25 J/cm
2 group,
and fibrosis and hemorrhage were observed within and outside of the adventitia in the 50 J/cm
2 and 100 J/cm
2 groups. Necrosis was observed in the submucosa and
muscle layer in the 25 J/cm
2 group and within and outside of the adventitia in the 50 J/cm
2 and 100 J/cm
2 groups. These changes tended to become more severe as
the irradiation dose increased.
doi:10.1371/journal.pone.0038308.t002
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the normal canine bronchi and a clinical study of human lung
cancer suggest that similar effects should be expected in humans
after double-irradiation doses that were used in dogs (unpublished
data). Therefore, we recommend that human clinical trials in the
esophagus should start with an irradiation dose of 50 J/cm
2, which
is similar to that used to treat lung cancer.
Laserphyrin PDT is expected to have a greater effect on the
deep-tissue layers compared with Photofrin PDT [13,14].
Laserphyrin PDT provides excellent clinical treatment responses
in patients with early lung cancer [15–17]. Laserphyrin PDT
might produce similar clinical effects when used to treat
esophageal disease, especially for salvage treatment after CRT
for esophageal cancer. If so, this would be advantageous for
patients because of the lower risk of phototoxicity and shorter
interval of light shielding.
This study has some limitations because we could not evaluate
the actual tumoricidal effect on esophageal cancer. However, it is
difficult to simulate exactly the human pathology and treatment in
an animal model. Tissue thickness and fragility differ between
humans and animal models. Establishing an esophageal cancer
model is difficult in a large animal model. To evaluate the direct
effects of Laserphyrin PDT on human esophageal cancer, we
carefully run a well-controlled clinical trial. Another limitation was
that we did not evaluate the effect by dose escalation of
Laserphyrin. However, the recommended timing of the irradiation
in humans has been established at a concentration of 20 mg/ml in
the plasma. Therefore, we believe that there is no need to estimate
another dose in clinical applications.
In conclusion, we have for the first time determined the safety
range of 25 J/cm
2 for irradiation with a diode laser in the canine
esophagus when the plasma concentration was around 20 mg/ml.
This information will be useful for planning clinical studies to
examine the effects of Laserphyrin PDT on various esophageal
diseases.
Materials and Methods
Animals
Male Beagle dogs weighing 12.0–14.7 kg and 13–14 months old
were used in this study. The site of laser irradiation was
determined as the area at 9 o’clock 5 cm oral to the esophago-
gastric junction, where it was possible to stably hold an endoscope
and irradiate with a laser. The sites at 5 o’clock and 3 o’clock were
marked in advance with a clip and tattooing as the landmarks for
irradiation.
This preclinical research was done at the Shinn Nihon
Biomedical Laboratories, Ltd. (Kagoshima, Japan) according to
the Good Laboratory Practice Guideline. All research and
experimental protocols were conducted according to the Regula-
tion for the Care and Use of Laboratory Animals of Shinn Nihon
Biomedical Laboratories and were approved by the Animal Care
and Use Committee of Shinn Nihon Biomedical Laboratories,
Ltd. (Approval ID: No. 704-006).
Photosensitizer
Laserphyrin (Meiji Seika Pharma, Tokyo, Japan) is a water-
soluble photosensitizer with a molecular weight of 799.69 and has
a chlorine annulus. Its maximum absorption peak is at a wave-
length of 407 nm, and there is a second peak at 664 nm.
Laserphyrin has high tumor affinity and is excited by visible red
light with a longer wavelength of 664 nm, enabling deeper
penetration into the tissue [12,13].
Laser Unit and Endoscope
A diode laser (ZH-L5011HJP, Panasonic Health Care,
Yokohama, Japan) emitting continuous-wave laser light at
a wavelength of 664 nm was used as the laser source for the
excitation of Laserphyrin. We used a straight-type fiber-optic tip
for the irradiation. An Olympus GIF-XQ240 endoscope and
a Panasonic PD laser device (ZH-L5011HJP) were used.
Protocol of Laserphyrin Photoactivation in the Normal
Esophagus
We fixed the dose of Laserphyrin because the profile of the
systematic side effects is known and has been confirmed for lung
cancer in a clinical study [14]. The approved dose of Laserphyrin
for humans is 1 mg/kg, and the interval between Laserphyrin
injection and laser exposure is 4–6 hours. In this condition, the
blood concentration of Laserphyrin is about 20 mg/ml (un-
published data by Meiji Pharma, Tokyo).
In this animal model, Laserphyrin was administered intrave-
nously into the cephalic vein or saphenous vein at a dose of
20 mg/kg. The time interval between photosensitizer injection
and laser exposure was 60 min because the concentration of
Laserphyrin in the blood during this interval was equal to that in
humans (20 mg/dl) (data not shown).
To investigate the tissue damage in relation to the energy of the
diode laser, dose escalation was set at 3 energy levels. The initial
dose was set at an energy level of 25 J/cm
2, and the second and
the third were at 50 J/cm
2 and 100 J/cm
2, respectively. These
three dosage groups comprised three dogs in each group.
Laser irradiation was applied under general anesthesia using
isoflurane. The target area was 1 cm
2 in the normal esophageal
mucosa in the 9 o’clock direction and 5 cm from the esophago-
gastric junction (Figure 5). To avoid missing the location of the
irradiated area, the sites at 5 o’clock and 3 o’clock were marked in
advance with a clip and tattooing by Indian ink, respectively, as
the landmarks for irradiation. The dogs were fasted, and only
water was given on the day of irradiation (day 0) and the next day
(day 1), and a liquid meal was fed from day 2.
Evaluation of the Effect of Laserphyrin Photoactivation in
the Normal Esophagus
To evaluate the response to Laserphyrin photoactivation,
changes on the surface of the whole esophagus including the
irradiated area were examined endoscopically on days 0, 1, and 7.
After the endoscopic examination on day 7, pentobarbital sodium
was injected intravenously to provide anesthesia, and the dogs
were exsanguinated for euthanasia. The internal organs and
tissues were observed macroscopically, fixed in formalin, and
subjected to hematoxylin and eosin staining for pathology
evaluation. To measure the Laserphyrin concentration in the
blood, blood was collected at the time of laser irradiation, which
was 60 min after administration.
To evaluate the systemic effects of Laserphyrin, blood was
collected from the external jugular vein before irradiation (day 0)
and on postirradiation days 1 and 7, and the inflammatory
reactions and hematological adverse effects were examined. To
determine whether there was reduced oral food intake, the amount
of leftover food from the previous day was recorded from day 2 to
day 7 and thereafter. Body weight was measured before irradiation
on day 0 and on day 7.
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